Compare Fluence Energy Inc. Class A Common Stock (FLNC) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fluence Energy Inc. Class A Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Fluence Energy Inc. Class A Common Stock trades at $6.15 (market cap $969.93M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 10.8× Fluence Energy Inc. Class A Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Fluence Energy Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluence Energy Inc. Class A Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| FLNC | PCVX | |
|---|---|---|
Market Cap | $969.93M | $10.51B |
Volume | 7,001,648 | 2,644,694 |
Sector | Utilities | Health |
52-Week High | $32.23 | $73.82 |
52-Week Low | $6.21 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.02B | $9.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fluence Energy Inc. Class A Common Stock
Fluence Energy Inc. designs and delivers energy storage products, operational services, and asset optimization software for renewable-energy and storage applications worldwide.
Read more on FLNC →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
